التفاصيل البيبلوغرافية
| العنوان: |
Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study. |
| المؤلفون: |
Nagalla, SR, Janaki, V, Vijayalakshmi, AR, Chayadevi, K, Pratibha, D, Rao, PV, Sage, KM, Nair‐Schaef, D, Bean, E, Roberts, CT, Gravett, MG, Nagalla, S R, Vijayalakshmi, A R, Rao, P V, Sage, K M, Nair-Schaef, D, Roberts, C T Jr, Gravett, M G |
| المصدر: |
BJOG: An International Journal of Obstetrics & Gynaecology; Dec2020, Vol. 127 Issue 13, p1687-1694, 8p |
| مصطلحات موضوعية: |
ASIANS, POINT-of-care testing, PREGNANCY proteins, PLACENTAL growth factor, PREECLAMPSIA, ASIAN studies, PREECLAMPSIA diagnosis, FIBRONECTINS, RESEARCH, MEDICAL information storage & retrieval systems, RESEARCH methodology, CASE-control method, EVALUATION research, SOUTHEAST Asians, MEDICAL care use, COMPARATIVE studies, CLINICAL medicine, RESEARCH funding, POVERTY, LONGITUDINAL method |
| مصطلحات جغرافية: |
INDIA |
| مستخلص: |
Objective: To determine the performance of a glycosylated fibronectin (GlyFn) point-of-care (POC) test for pre-eclampsia (PE) in a large Southeast Asian cohort (India) in comparison to previously described biomarkers.Design: A total of 798 pregnant women at ≥20 weeks of gestation were enrolled in a prospective case-control study. Study participants included 469 normotensive women with urinary mg protein/mmol creatinine ratio <0.3, 135 with PE (hypertension with urinary mg protein/mmol creatinine ratio ≥0.3) and 194 with gestational hypertension (hypertension with urinary mg protein/mmol creatinine ratio <0.3).Methods: GlyFn levels were determined using a POC device and PIGF, sFlt-1 and PAPPA2 levels were determined by immunoassay. Performance was assessed using logistic regression modelling and receiver-operating characteristic (ROC) curves. Classification performance and positive and negative predictive values are reported at specific thresholds.Results: Increased levels of GlyFn, soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy-associated placental protein A2 (PAPPA2), and decreased levels of placental growth factor (PlGF) were significantly associated (P < 0.01) with clinically defined PE. Area under the ROC (AUROC) values with 95% confidence intervals were: GlyFn, 0.99 (0.98-0.99); PlGF, 0.96 (0.94-0.98); sFlt-1, 0.86 (0.83-0.89); and PAPPA2, 0.96 (0.94-0.97). Of subjects with GH, 48% were positive for more than two PE biomarkers, and 70% of these delivered preterm.Conclusions: The Lumella™ GlyFn POC test has been validated in a low/middle-income country setting for PE diagnosis and may be a useful adjunctive tool for early identification, appropriate triage, and improved outcomes.Tweetable Abstract: The Lumella™ point-of-care test had excellent performance in diagnosing PE in a large Southeast Asian cohort. [ABSTRACT FROM AUTHOR] |
|
Copyright of BJOG: An International Journal of Obstetrics & Gynaecology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
